

Missouri Pharmacy Program - Preferred Drug List



Skeletal Muscle Relaxants

Effective 12/24/2008 Revised 04/02/2015

Preferred Agents

(Available with clinical edits)

- Baclofen
- Chlorzoxazone
- Cyclobenzaprine
- Methocarbamol
- Tizanidine Tabs
- Orphenadrine
- Orphenadrine Compound
- Orphenadrine ER
- Metaxalone

Non-Preferred Agents

(Available with clinical edits)

- Soma®
- Soma® Compound
- Zanaflex® Tabs/Caps
- Flexeril®
- Robaxin®
- Dantrium®
- Parafon Forte DSC®
- Fexmid®
- Amrix®
- Norflex®
- Tizanidine Caps
- Lioresal®
- Carisoprodol
- Carisoprodol Compound
- Dantrolene®
- Lorzone®
- Cyclobenzaprine ER
- Skelaxin®

Approval Criteria	<u>Denial Criteria</u>
Duration of therapy limit – Agents for musculoskeletal	Therapy will be denied if no approval criteria
conditions	are met
• 2 courses of therapy – 6 weeks maximum for each	
course annually	
• Agents for muscle spasticity exempt from therapy	
duration limitation	
 Baclofen 	
 Tizanidine 	
 Metaxalone 	
 Dantrium 	
 Dantrolene 	
 Methocarbamol 	

Failure to achieve desired therapeutic outcomes with	Lack of adequate trial on required preferred
trial on 5 or more preferred agents	agents
 Documented trial period for preferred agents 	
 Documented ADE/ADR to preferred agents 	
Documented compliance on current therapy regimen	Drug Prior Authorization Hotline: (800) 392-
	8030